Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALT NASDAQ:AMRN NASDAQ:EPIX NASDAQ:PVLA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALTAltimmune$3.61-2.2%$5.14$2.90▼$11.16$299.29M-0.013.61 million shs1.80 million shsAMRNAmarin$15.16+4.4%$14.46$7.08▼$17.49$300.67M0.8481,295 shs88,516 shsEPIXESSA Pharma$1.88$1.76$1.40▼$7.88$83.45M1.55476,027 shs153,036 shsPVLAPalvella Therapeutics$36.55-0.1%$27.01$11.17▼$40.50$404.42M-0.02173,996 shs56,129 shs7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALTAltimmune-2.17%-11.52%-26.33%-37.44%-43.24%AMRNAmarin+4.41%-1.49%-8.95%+38.96%+11.14%EPIXESSA Pharma0.00%0.00%+10.59%+8.67%-64.86%PVLAPalvella Therapeutics-0.08%-5.36%+53.38%+49.43%+3,654,999,900.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationALTAltimmune2.2651 of 5 stars3.43.00.00.01.31.70.6AMRNAmarin0.5907 of 5 stars0.55.00.00.01.80.00.6EPIXESSA Pharma1.1674 of 5 stars1.05.00.00.00.02.51.3PVLAPalvella Therapeutics2.6683 of 5 stars3.60.00.00.02.52.50.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALTAltimmune 2.75Moderate Buy$18.20404.16% UpsideAMRNAmarin 1.00Sell$12.00-20.84% DownsideEPIXESSA Pharma 2.00Hold$2.006.38% UpsidePVLAPalvella Therapeutics 3.11Buy$47.5029.96% UpsideCurrent Analyst Ratings BreakdownLatest EPIX, ALT, AMRN, and PVLA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/21/2025PVLAPalvella TherapeuticsTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$56.007/10/2025ALTAltimmuneThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong Sell7/10/2025ALTAltimmuneJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetMarket Outperform ➝ Market Outperform$25.00 ➝ $15.006/27/2025ALTAltimmuneWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Perform ➝ Market Perform6/27/2025ALTAltimmuneHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$12.006/25/2025AMRNAmarinThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetSell ➝ Sell$7.00 ➝ $12.005/16/2025PVLAPalvella TherapeuticsCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$53.00 ➝ $52.00(Data available from 8/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALTAltimmune$20K14,640.36N/AN/A$1.74 per share2.07AMRNAmarin$228.61M1.37N/AN/A$22.45 per share0.68EPIXESSA PharmaN/AN/AN/AN/A$2.81 per shareN/APVLAPalvella Therapeutics$42.81M9.44N/AN/A$5.58 per share6.55Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALTAltimmune-$95.06M-$1.26N/AN/AN/A-451,200.00%-65.44%-58.43%8/6/2025 (Estimated)AMRNAmarin-$82.18M-$3.67N/AN/AN/A-47.22%-21.18%-15.00%N/AEPIXESSA Pharma-$28.54M-$0.63N/AN/AN/AN/A-23.48%-22.86%8/4/2025 (Estimated)PVLAPalvella Therapeutics-$17.43M-$12.10N/AN/AN/AN/A-60.29%-43.30%8/13/2025 (Estimated)Latest EPIX, ALT, AMRN, and PVLA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025ALTAltimmune-$0.3006N/AN/AN/A$0.00 millionN/A8/13/2025Q2 2025PVLAPalvella Therapeutics-$0.81N/AN/AN/AN/AN/A8/4/2025Q3 2025EPIXESSA Pharma-$0.2430N/AN/AN/AN/AN/A7/30/2025Q2 2025AMRNAmarin-$0.66-$0.03+$0.63-$0.03$45.45 million$72.74 million5/15/2025Q1 2025PVLAPalvella Therapeutics-$3.40-$0.74+$2.66-$0.74N/AN/A5/13/2025Q1 2025ALTAltimmune-$0.35-$0.26+$0.09-$0.26$0.00 million$0.01 million5/8/2025Q2 2025EPIXESSA Pharma-$0.19-$0.14+$0.05-$0.14N/AN/A5/7/2025Q1 2025AMRNAmarin-$0.06-$0.04+$0.02-$0.04$50.75 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALTAltimmuneN/AN/AN/AN/AN/AAMRNAmarinN/AN/AN/AN/AN/AEPIXESSA PharmaN/AN/AN/AN/AN/APVLAPalvella TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALTAltimmuneN/A15.8515.85AMRNAmarinN/A3.262.55EPIXESSA PharmaN/A67.1567.15PVLAPalvella TherapeuticsN/A8.848.84Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALTAltimmune78.05%AMRNAmarin22.25%EPIXESSA Pharma75.12%PVLAPalvella Therapeutics40.11%Insider OwnershipCompanyInsider OwnershipALTAltimmune4.10%AMRNAmarin3.30%EPIXESSA Pharma15.50%PVLAPalvella Therapeutics20.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALTAltimmune5081.11 million77.78 millionOptionableAMRNAmarin36020.71 million20.02 millionOptionableEPIXESSA Pharma5044.39 million37.51 millionOptionablePVLAPalvella TherapeuticsN/A11.06 million8.79 millionN/AEPIX, ALT, AMRN, and PVLA HeadlinesRecent News About These CompaniesRoyce & Associates LP Invests $2 Million in Palvella Therapeutics, Inc. (NASDAQ:PVLA)July 29, 2025 | marketbeat.comPalvella Therapeutics, Inc. (NASDAQ:PVLA) Receives Consensus Rating of "Buy" from BrokeragesJuly 28, 2025 | marketbeat.comTruist Financial Initiates Coverage on Palvella Therapeutics (NASDAQ:PVLA)July 23, 2025 | americanbankingnews.comPalvella Therapeutics (NASDAQ:PVLA) Now Covered by Truist FinancialJuly 21, 2025 | marketbeat.comPVLA - Palvella Therapeutics Inc Sustainability - MorningstarJuly 9, 2025 | morningstar.comMPalvella Therapeutics Completes Enrollment for Pivotal Phase 3 Trial of QTORIN RapamycinJuly 9, 2025 | msn.comPalvella Therapeutics, Inc. (NASDAQ:PVLA) Given Consensus Recommendation of "Buy" by AnalystsJuly 3, 2025 | marketbeat.comPalvella Therapeutics, Inc. Added to Russell 3000® and Russell 2000® Indexes as of June 30, 2025June 30, 2025 | quiverquant.comQPalvella Therapeutics Added to Russell 3000® and Russell 2000® IndexesJune 30, 2025 | globenewswire.comPVLA - Palvella Therapeutics Inc Key Metrics - MorningstarJune 27, 2025 | morningstar.comMPVLA - Palvella Therapeutics Inc Executives - MorningstarJune 26, 2025 | morningstar.comMPalvella Therapeutics Completes Enrollment in Phase 3 SELVA Trial of QTORIN™ Rapamycin for Microcystic Lymphatic Malformations, Exceeding Enrollment Target by Over 25% | The ...June 24, 2025 | manilatimes.netMPalvella Therapeutics Completes Enrollment in Phase 3 SELVA Trial of QTORIN™ Rapamycin for Microcystic Lymphatic Malformations, Exceeding Enrollment Target by ... - MorningstarJune 24, 2025 | morningstar.comMPalvella Therapeutics Completes Enrollment for Phase 3 Trial of QTORIN™ Rapamycin in Microcystic Lymphatic Malformations, Anticipates Top-Line Data in 2026 - NasdaqJune 24, 2025 | nasdaq.comPalvella Therapeutics Announces Completion of Phase 3 SELVA Trial for QTORIN RapamycinJune 24, 2025 | msn.comPalvella Therapeutics Completes Enrollment for Phase 3 Trial of QTORIN™ Rapamycin in Microcystic Lymphatic Malformations, Anticipates Top-Line Data in 2026June 23, 2025 | quiverquant.comQPalvella Therapeutics Completes Enrollment in Phase 3 SELVA Trial of QTORIN™ Rapamycin for Microcystic Lymphatic Malformations, Exceeding Enrollment Target by Over 25%June 23, 2025 | globenewswire.comPalvella Therapeutics Granted Sixth U.S. Patent Covering 0.1–20% Anhydrous Compositions of Rapamycin and Other mTOR InhibitorsJune 18, 2025 | globenewswire.comPalvella Therapeutics Secures FDA Grant Funding for Phase 3 Trial of QTORIN RapamycinJune 13, 2025 | msn.comPalvella Therapeutics Secures FDA Orphan Products Grant to Support Phase 3 SELVA Trial of QTORIN™ for Microcystic Lymphatic MalformationsJune 9, 2025 | quiverquant.comQPalvella Therapeutics Receives Initial Proceeds from FDA Orphan Products Grant to Support Phase 3 SELVA Trial of QTORIN™ Rapamycin for Microcystic Lymphatic MalformationsJune 9, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesRocket Lab: A Parabolic Run Meets a Healthy PullbackBy Ryan Hasson | July 23, 2025View Rocket Lab: A Parabolic Run Meets a Healthy PullbackForget the Weak Dollar—These 3 Travel Stocks Are Still Taking OffBy Chris Markoch | July 6, 2025View Forget the Weak Dollar—These 3 Travel Stocks Are Still Taking OffDo They Know Something? Insiders & Congress Buy UnitedHealthBy Brian O'Connell | July 9, 2025View Do They Know Something? Insiders & Congress Buy UnitedHealthInsiders Spent Millions on These 3 Stocks Over the Past 2 MonthsBy Leo Miller | July 17, 2025View Insiders Spent Millions on These 3 Stocks Over the Past 2 MonthsHealthcare Stocks Hit Valuation Bottom, 3 Names to ReboundBy Gabriel Osorio-Mazilli | July 23, 2025View Healthcare Stocks Hit Valuation Bottom, 3 Names to ReboundEPIX, ALT, AMRN, and PVLA Company DescriptionsAltimmune NASDAQ:ALT$3.61 -0.08 (-2.17%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$3.64 +0.04 (+0.97%) As of 08/1/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.Amarin NASDAQ:AMRN$15.16 +0.64 (+4.41%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$15.08 -0.09 (-0.56%) As of 08/1/2025 06:24 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, European countries, Canada, Lebanon, and the United Arab Emirates. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. It sells its products principally to wholesalers and specialty pharmacy providers. The company has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland.ESSA Pharma NASDAQ:EPIX$1.88 0.00 (0.00%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$1.88 0.00 (0.00%) As of 08/1/2025 07:18 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses the development of small molecule drugs for the treatment of prostate cancer. The company's lead candidate EPI-7386, an androgen receptor based resistance mechanisms that develop in patients with castration-resistant prostate cancer and metastatic castration-resistant prostate cancer. It has collaboration agreements with Bayer Consumer Care AG; Janssen Research & Development, LLC; and Astellas Pharma Inc. ESSA Pharma Inc. was incorporated in 2009 and is headquartered in Vancouver, Canada.Palvella Therapeutics NASDAQ:PVLA$36.55 -0.03 (-0.08%) As of 08/1/2025 04:00 PM EasternPalvella Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases. Palvella Therapeutics Inc., formerly known as Pieris Pharmaceuticals Inc., is based in WAYNE, Pa. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/28 - 08/01 Alphabet Gains Momentum as Sentiment on Wall Street Improves Amazon's Earnings: What Comes Next and How to Play It Apple Stock: Big Earnings, Small Move—Time to Buy? Tesla Teams With Samsung—Will Other Chipmakers Follow? Will Hims & Hers Fall Along With Novo Nordisk? UPS's 7.5% Dividend: A Blue-Chip Stock on a Once-in-a-Decade Sale AbbVie Stock Eyes Breakout as Pipeline and Profits Grow Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
